U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199127) titled 'Duodenal Polyposis Classification in FAP' on Sept. 22.
Brief Summary: Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia. The DRACO study (Duodenal Risk Assessment in adenomatous polyposis Coli -Oncogene) is a multicenter, STROBE- and CONSORT-compliant cohort study that analyzes upper endoscopies from genetically confirmed FAP patients across independent cohorts to develop, validate, and externally test two multivariable risk models.
Study Start Date: Feb. 02, 2018...